Arizona Tribune - Boulevard

Hopes fade in Colombia as window to find quake survivors shuts

Hopes faded and camps housing Colombian quake victims grew on Thursday, as the critical 72-hour window for finding people alive closed for good.

US, Mexico conduct security exercises near border

US and Mexican armed forces performed security exercises Thursday along the border near the cities of El Paso and Ciudad Juarez.

Revive Therapeutics Reports Grant of Options

TORONTO, ON / ACCESS Newswire / August 14, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced the Board of Directors of Revive has authorized the grant of an aggregate of 15,500,000 incentive stock options to key members of our team, including directors, officers, and consultants. The stock options have an exercise price of $0.05 per share for a period of five years. All Options were granted pursuant to the Company's 10% rolling stock option plan (the "Plan") and are subject to the terms of the Plan, the applicable grant agreement and the requirements of the CSE. These stock options are an essential component of our strategy to drive performance and incentivize excellence as we advance our corporate objectives.

Kultura Brands Establishes Authorized Share Ceiling and Next Phase of Capital Structure Reform

Company Sets 50 Billion Authorized Common Share Ceiling and Signals Additional Capital Structure Reductions as Legacy Obligations Are Resolved

DataMEDS AI Announces Its Board of Directors Approved September 9, 2026 as the Payment Date of the Previously Announced Distribution of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of August 7, 2026

TAMPA, FL / ACCESS Newswire / August 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMEDS AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant delivery of healthcare and monetization of health data by market participants, today announced that its board of directors (the "Board") fixed September 9, 2026 (the "Payment Date") as the date on which the previously announced distribution (the "Distribution") of Dream Bowl Meme Coin I tokens (the "Dream Bowl Tokens") will be paid to record stockholders of DataMEDS (, the "Record Holders") as of the close of business on August 7, 2026 (the "Record Date").

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

WINNIPEG, MB / ACCESS Newswire / August 14, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2026 and will have a conference call to present the Financial Results on August 17, 2026 at 8:30 am Eastern Time.

ShimmerScreen(R) Launches New Online Store

The new e-commerce platform allows customers to configure, price, and purchase custom ShimmerScreen installations up to 100 square feet in seconds.

AI Search Engineers Introduces Answer Engine Optimization Services for Medical Practices, Documenting the AI Search Visibility Gap Keeping Physicians, Specialists and Healthcare Providers Invisible in ChatGPT and Google Gemini

Internal analysis from AI Search Engineers identifies the medical industry as one of the most significant untapped AI search opportunity categories in professional services, with most physician practices, specialist offices and healthcare providers scoring below 35 out of 100 on AI search authority before any engagement.

TRNR Reports Record Q2 2026 Results, Driven by 445% Revenue Growth; Confirms 2026 Pro Forma Revenue Guidance of More Than $50m and Q4 Profitability

Q2 2026 Reported Revenue of $6.6 Million, a 445% Increase Compared to Q2 2025Adjusted EBITDA (non-GAAP) Loss Reduced to $0.6 Million From $1.8 Million in Q1 2026Company Expects 2026 Pro Forma Revenue of More Than $50 Million and Adjusted EBITDA Profitability in Q4STEPR Acquisition Expected to Close in the Fourth Quarter of 2026 and M&A pipeline is strong

Kartoon Studios Reports Second Quarter 2026 Financial Results and Accelerates Strategic Transformation

8-K Filed Announcing Agreement with Amazon PrimeStrengthened Balance Sheet with $40 million in Cash and No Long-Term DebtFocus on Intellectual Property Ownership for Next Phase of Growth

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology PipelineNon-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor StrategyStrategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity

CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with antibody-mediated rejection (AMR) in organ transplant and various autoimmune diseases, today reported business and financial results for the first half year ended June 30, 2026.

InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 14

LONDON, UK / ACCESS Newswire / August 14, 2026 / The Company announces that on 13 August 2026 it purchased the following number of its ordinary shares of 20340/399pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.

'Dream come true': Owners reunite with pets in quake-hit Colombia

A beaming Vickye Giraldo holds her rescued kitten tight against her chest outside her ruined home in quake-hit Cali, Colombia.

Israel reopens once-closed West Bank settlement

Israel officially reopened the West Bank settlement of Ganim on Thursday, more than 20 years after it withdrew from the community, in a move emblematic of the current government's policy of rapid settlement expansion.

Colombia rescuers cling to hope as quake survival window closes

Rescuers in Colombia made a last-ditch effort to locate earthquake survivors early Thursday, as the critical 72-hour window for finding people alive drew to a close.

Porsche to end production of flagship electric car: report

Struggling German sports car maker Porsche plans to end production of the Taycan, its flagship fully electric model, by 2030 after steadily dwindling sales, a report said Thursday.

Blaze forces families to abandon Turkish tour boat

More than 100 people had to abandon ship after a fire engulfed a children's entertainment tour boat off southwestern Turkey on Thursday, officials said.

British eccentrics push humble garden shed to new heights

"Welcome to the Shanty Shed," shouted steam ship enthusiast Peter McLaughlin over the din of pistons lunging back and forth as clouds of white vapour billowed from his London garden hideaway.

FBI Curaleaf Report Signals Federal Scrutiny Ahead for State Marijuana Operators Seeking DEA Registration

The FBI released 64 pages and withheld 147 more, most of them protected under grand jury secrecy rules. The records were provided to The Newsground by researcher Joe Lloyd, who filed the FOIA request for FBI materials mentioning Curaleaf.MMJ International Holdings says entry into the federal controlled-substances system may expose applicants' ownership, financing, compliance histories and diversion controls to scrutiny far beyond state licensing reviews.

Vogenx Announces Closing of Initial Public Offering

RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the closing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $13.00 per share. All of the shares were offered by Vogenx. The gross proceeds to Vogenx from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $81.3 million.

Humanoid Judge Tries Simulated Case

Sophia the Robot presides over a mock courtroom case during the 2026 Burton Awards, exploring the intersection of artificial intelligence, law, and legal innovation.

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET

Newsmax Announces Second Quarter 2026 Financial Results

Company Reports Record Quarterly Revenues of $54.1 million, a 16.5% Year-Over-Year IncreaseBroadcast Revenues Increase to $45.8 million, a 20.5% Increase Year-Over-YearCompany Reports Net Income of $2.9 million and Adjusted EBITDA of $5.7 million, Its First Profitable Quarter as a Public Company

Tenon Medical Reports Second Quarter 2026 Financial Results

~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~~ Second Quarter Gross Profit of $0.8 Million, a 232% Increase Compared to Prior Year; Gross Margin of 64% ~~ Received FDA 510(k) Clearance for Updated Catamaran® SI Joint Fusion System ~~ Physician and Distributor Training Events Increased 98% in 1H 2026 Compared to 2H 2025, Supporting Record Monthly Case Volume in July 2026 ~~ Closed $4.2 Million Public Offering Subsequent to Quarter End ~

CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026.

NextBoat Inc. Announces Fiscal Second Quarter 2026 Results

Second quarter 2026 revenue increased 88.4% year-over-year to a record $59.1 millionRecord number of units transacted, 138% year-over-year increase

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company has issued new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire on the five-year anniversary of the date of such stockholder approval. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-288061), Form S-1MEF (File No. 333-288134), Form S-3 (File No. 333-284969) and Form S-3 (File No. 333-283983).

Dr. Louis DeJoseph Outlines Important Considerations for Neck Lift Candidates

Dr. Louis DeJoseph reviews who may benefit from a neck lift and why surgeon credentials, aesthetic style, and realistic expectations matter when considering treatment.

Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase

Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry begins technical assessment • Regulatory requirements defined • Potential decision as early as Q4 2026Near-Term Regulatory CatalystFormal review underway: Ukraine's Ministry of Health accepted the Entolimod dossier for formal review on July 22, 2026.Technical assessment underway: Ukraine's Ministry of Health has begun technical assessment of the dossier and issued its first round of questions, relating to the physicochemical characterization of the drug product that would be supplied under a potential stockpiling arrangement.Defined pathway: The Company has identified the analytical testing, quality-control validation, GMP verification, import-documentation, and Ukrainian-language labeling requirements applicable to the registration process.Potential Q4 decision: Valion Bio believes a regulatory decision could occur as early as the fourth quarter of 2026; there can be no assurance regarding timing or outcome.First potential national registration: A favorable decision would represent Entolimod's first national registration.Potential government-market pathway: Registration could establish a pathway toward possible inclusion in Ukraine's national strategic reserves and future government procurement. No procurement, purchase, or stockpiling agreement has been executed.

MDCE Highlights StrainScan Pro for Multi-Billion-Dollar Cannabis Dispensary Sector with Enterprise iPad Air Solution (OTC Pink:MDCE)

Proprietary AI Vision Platform Delivers Rapid Strain Identification and Quality Verification Tools for Licensed Multi-Location Dispensary Operators

BODYWELLE Brings Professional Football-Level Recovery to Miami Beach With EMSculpt NEO

The Miami Beach practice offers the same EMSculpt NEO platform recently added to a professional football team's recovery program, including its functional health and rehabilitation protocols.

RBGPF	0.5%	69.35	$
BCC	-1.66%	81.77	$
CMSC	-0.38%	21.28	$
RYCEF	-0.88%	20.42	$
CMSD	-0.14%	21.12	$
JRI	0.24%	12.41	$
NGG	-0.05%	80.62	$
VOD	-1%	16.01	$
RELX	0.79%	35.38	$
BCE	0.34%	23.78	$
RIO	1.69%	102.17	$
GSK	-1.77%	51.96	$
BTI	1.27%	56.7	$
AZN	-0.28%	164.49	$
BP	3.12%	45.14	$

Arizona Tribune - Boulevard (English)

Featured

Maradona trial on hold over possible medical evidence mix-up

What a record-breaking El Nino could mean for the world

Last news